Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2023-12-06 Capital/Financing Update
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by BioCardia, Inc. It details an At The Market Offering Agreement for selling common stock, including terms of the agreement, commission, and forward-looking statements. The document does not contain financial statements or detailed financial analysis but is an announcement of a financing activity. The presence of the Sales Agreement as an exhibit supports this. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (8142 characters) and content confirm it is not a brief announcement or a full financial report but a substantive update on capital raising.
2023-12-06 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement and accompanying prospectus related to an 'At The Market Offering' of common stock. It details the terms of the offering, the sales agreement with an underwriter, risk factors, use of proceeds, and other offering-related information. This type of filing is a capital raising document used to update or supplement a shelf registration statement for securities offerings. It is not a financial report, earnings release, management discussion, or any other report type. It clearly relates to financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not a brief announcement or regulatory filing. Confidence is high due to explicit references to the offering and sales agreement.
2023-12-06 English
Regulatory Filings 2023
Regulatory Filings
2023-12-06 English
FORM 8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It updates the original report with information about the company's decision on the frequency of future stockholder advisory votes on executive compensation. The document references a proxy statement and voting results from the 2023 Annual Meeting but does not contain detailed financial data or a full report. It is primarily an update on voting matters related to executive compensation, which aligns with Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3566 characters, which is relatively short and focused on voting results rather than a full report or presentation. Therefore, the best classification is DVA with high confidence.
2023-12-05 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by BioCardia, Inc. It announces an extension of the deadline for shareholder proposals for the 2024 Annual Meeting, which is a regulatory update related to shareholder meeting procedures. The content is brief (under 5,000 characters) and does not contain financial statements or detailed financial data. It is not a full report like an Annual Report or Proxy Statement but rather a regulatory announcement about a procedural change. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-05 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from BioCardia, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration process, specifically requesting the SEC to declare the registration statement effective at a certain date and time. The document does not contain financial statements, audit information, earnings data, or any detailed report content. It is a regulatory filing related to capital markets and securities registration but is not itself a financial report or earnings release. Given the nature of the document as a formal SEC correspondence requesting acceleration of a registration statement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2023-12-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.